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Abstract An X-linked condition characterized by the
combination of hypomyelinating leukodystrophy and
spondylometaphyseal dysplasia (H-SMD) has been observed
in only four families, with linkage to Xq25-27, and recent ge-
netic characterization in two families with a common AIFM1
mutation. In our study, 12 patients (6 families) with H-SMD
were identified and underwent comprehensive assessment ac-
companied by whole-exome sequencing (WES). Pedigree anal-
ysis in all families was consistent with X-linked recessive inher-
itance. Presentation typically occurred between 12 and
36 months. In addition to the two disease-defining features of
spondylometaphyseal dysplasia and hypomyelination on MRI,
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common clinical signs and symptoms included motor deteriora-
tion, spasticity, tremor, ataxia, dysarthria, cognitive defects, pul-
monary hypertension, nystagmus, and vision loss due to retinop-
athy. The course of the disease was slowly progressive. All
patients had maternally inherited or de novo mutations in or near
exon 7 of AIFM1, within a region of 70 bp, including synony-
mous and intronic changes. AIFM1 mutations have previously
been associated with neurologic presentations as varied as intel-
lectual disability, hearing loss, neuropathy, and striatal necrosis,
while AIFM1 mutations in this small region present with a dis-
tinct phenotype implicating bone. Analysis of cell lines derived
from four patients identified significant reductions in AIFM1
mRNA and protein levels in osteoblasts. We hypothesize that
AIFM1 functions in bone metabolism and myelination and is
responsible for the unique phenotype in this condition.
Keywords Hypomyelination . Spondylometaphyseal
dysplasia .Whole exome sequencing (WES) . AIFM1 gene .
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Introduction
Hypomyelinating leukodystrophies are a heterogeneous group
of genetic disorders characterized by a permanent, significant
lack of myelin on brain MR imaging [1, 2]. The archetype of a
hypomyelinating disorder, Pelizaeus-Merzbacher disease
(PMD), is caused by alterations of PLP1, encoding the most
abundant structural myelin protein, proteolipid protein 1.
However, as new genetic techniques have identified novel
genetic causes of hypomyelination, genes coding for structural
proteins are not commonly identified. Rather, most genes
identified encode proteins involved in RNA metabolism and
protein synthesis [3]. How mutations in these genes affect
central nervous system (CNS), myelination is still not well
understood.
A distinctive hypomyelinating leukodystrophy character-
ized by the combination of hypomyelination and
spondylometaphyseal dysplasia (H-SMD) was first described





















1 Department of Human Genetics, Yokohama City University
Graduate School of Medicine, Fukuura, Kanazawa-ku,
Yokohama 236-0004, Japan
2 Department of Child Neurology, and Amsterdam Neuroscience, VU
University Medical Center, De Boelelaan 1117, 1081
HVAmsterdam, the Netherlands
3 Department of Clinical Genetics, VU University Medical Center, De
Boelelaan 1117, 1081 HVAmsterdam, the Netherlands
4 Center for Biomedical Research, Faculty of Medicine, Diponegoro
University, Semarang, Indonesia
5 Institute for Molecular Bioscience, The University of Queensland,
Brisbane, Australia
6 University Children’s Hospital, University Medical Center Hamburg
Eppendorf, Martinistr. 52, 20246 Hamburg, Germany
7 Department of Diagnostic Imaging and Radiology, Children’s
National Medical Center, Washington, DC, USA
8 Department of Neurology, Children’s National Medical Center, Suite
4800, Washington, DC, USA
9 Division of Medical Genetics, A.I. duPont Hospital for Children/
Nemours, Wilmington, DE, USA
10 Department of Pediatric Neurology, Univ.-Klinikum Giessen/
Marburg; Standort Giessen, Feulgenstr. 12, 35389 Giessen, Germany
11 Chesterford Research Park, Illumina, Inc., Little Chesterford CB10
1XL, UK
12 Department of Pediatrics, Osaka University Graduate School of
Medicine, Osaka, Japan
13 Illumina, Inc, San Diego, CA, USA
14 Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts
General Hospital and Harvard Medical School, Boston, MA, USA
15 Stanley Center for Psychiatric Research, Broad Institute,
Cambridge, USA
16 Department of Genetics, University Medical Center Groningen,
University of Groningen, Groningen, The Netherlands
17 Department of Child Neurology, University Hospital Groningen,
Groningen, Netherlands
18 Division of Genetic Medicine, Centre Hospitalier Universitaire
Vaudois (CHUV), University of Lausanne, Lausanne, Switzerland
19 George Washington University School of Medicine,
Washington, DC, USA
20 Department of Pediatrics, Hamamatsu University School of
Medicine, Hamamatsu 431-3192, Japan
21 Children’s Hospital of Philadelphia, Philadelphia, PA, USA
186 Neurogenetics (2017) 18:185–194
(MIM 300232) [5]. Myelin deficit was confirmed in the brain
tissue of a deceased patient, with reduced numbers of oligo-
dendrocytes accompanied by astrocytosis [4]. Although an X-
linked pattern of inheritance and linkage to Xq25-27 had al-
ready been identified in the first family,4, 6 H-SMD could not
be associated to a specific causative gene until recently, when
it was linked with a single missense mutation in AIFM1,
encoding mitochondrial apoptosis-inducing factor 1
(AIFM1). This was reported in a Polish family and originally
published without MRI findings [6] and in an unrelated Polish
family carrying an identical p.(Asp237Gly) mutation [7].
In this study, we present 12 patients with H-SMD, the larg-
est series thus far, all with AIFM1 variants confined to a locus
of approximately 70 bp around the start of exon 7, including
synonymous and intronic variants not predicted to be patho-
genic by in silico modeling. Thus, we hypothesize that the
unique features of this disorder might be caused by tissue-
specific loss of functional AIFM1. Variants in AIFM1 have
been shown to be associated with diverse neurological disor-
ders featuring intellectual disability, sensory hearing loss, neu-
ropathy, and an encephalopathy associated with striatal abnor-
malities on neuroimaging. The present cohort adds to the dis-
ease spectrum associated with AIFM1, expanding on the sin-
gle variant previously associated with H-SMD.
Methods
Patients
The affected individuals and their families were collected pro-
spectively as part of bioregistries including the Myelin
Disorders Bioregistry Project (MDBP) at Children’s
National Health System, the Amsterdam Center for
Childhood White Matter Disorders and the Yokohama City
University Graduate School of Medicine with approval from
the institutional review boards at the respective institutions.
Written informed consent was obtained for each study partic-
ipant including specific informed consent for whole-exome
sequencing (WES). Genomic DNA samples were collected
from blood samples provided to the biorepository. Patient 4
[5] and patients 9–12 [4] were previously published.
Exome and genome sequencing
WES or whole-genome sequencing (WGS) was performed for
individual families to identify causative genes. Exomes were
captured using the SeqCap EZHuman Exome Library v.3.0 or
SureSelect HumanAll Exon V5 and sequenced on an Illumina
HiSeq 2000 with 100-bp paired-end read-sequencing proto-
col. Sequencing was performed at the Queensland Centre for
Medical Genomics (patient 1), at the Yokohama City
University Graduate School of Medicine (patients 2 and 3),
at the Department of Genetics, Groningen sequencing center
(patient 5–7), and at the University Klinikum Giessen/
Marburg (patients 8–12). Two patients (patients 1 and 6) were
also analyzed by whole-genome sequencing (WGS), per-
formed by Illumina Inc. in the Illumina Clinical Services
Laboratory (San Diego, CA) or in the Illumina United
Kingdom sequencing facility in Chesterford, England. Data
analysis and variant calling approaches are described in sup-
plemental data. One individual (patient 4) had not consented
to next-generation sequencing; therefore, standard Sanger se-
quencing for AIFM1 was subsequently performed in view of
clinical similarities with other cases. Intron 6 and exon 7 se-
quences from AIFM1 across 15 mammalian species were ob-
tained via Ensembl (www.ensembl.org, last accessed on 10
February 2017) to develop sequence logos using WebLogo
(http://weblogo.berkeley.edu, last accessed on 10 February
2017).
Imaging
The latest available MRI was analyzed for this study. MRIs
were evaluated according to a previously published protocol
[8] for hypomyelination, according to previously definedMRI
criteria [9] by N.I.W. and A.V. Clinically obtained bone radio-
graphs were reviewed by D.B. and included skeletal surveys,
skull, hand, long bone, hip, and spine films as available.
Review of clinical findings
Clinical findings were retrospectively collected by review of
medical records and testing, and if individuals were available
for clinical evaluation, verification of specific findings and
features was performed in a prospective fashion.
AIFM1 expression
Cell transdifferentiation/creation of osteoblasts
Transdifferentiation was performed on patient fibroblasts at
confluence 90% by adding osteogenic transdifferentiation me-
dium (α-MEM medium (Life Technologies) supplemented
with 5 mM β-glycerophosphate (Sigma-Aldrich), 90 μg/ml
L-ascorbic acid-2-phosphate (Sigma-Aldrich), 5000 U/ml
Penicillin-Streptomycin (Life Technologies), and 5% platelet
lysate [8, 10]. After 21 days, Alizarin Red, alkaline phospha-
tase (ALP) activity, and von Kossa staining were performed to
characterize osteogenic properties [9, 11, 12]. The
transdifferentiation experiments were repeated three times
for every patient cell line except for patient 1 (repeated twice).
qPCR RNA was extracted from transdifferentiated cells on
days 2, 3, 7, 14, and 21. qPCR was performed in the Light
Cycler® 480 (Roche) for AIFM1 (NM_004208.3) and
YWHAZ as housekeeping gene. In order to validate osteogenic
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transdifferentiation, qPCR of osteoblast markers RUNX2 and
ALP was performed (see also supplementary methods). The
qPCR results were analyzed with LightCycler 480 software
1.5.1 (Roche) and normalized to housekeeping gene expres-
sion. qPCR results were expressed as mean of two indepen-
dent experiments performed in duplicate for every sample.
Differences were analyzed with the use of the paired sample
t test using GraphPad Prism 6. Differences were considered
significant when p < 0.05. As cell lines of patient 1 were
received later, analysis was performed separately and only
qualitatively. Primers are available in supplemental methods.
Western blot Whole cell lysates of fibroblasts and
transdifferentiated osteoblasts were subjected to electrophore-
sis for 50 min at 200 Von NuPage 4–12% BIS-TRIS gel with
NuPAGE MOPS Running Buffer (Invitrogen). After protein
transfer and blocking, the nitrocellulose membrane was incu-
bated with primary antibodies for AIFM1 (Abcam; cat no.
AB1998) and actin (Abcam; cat no. AB 14128) overnight
at 4 °C. After 1 h incubation with secondary antibody
IRDye 800 CW goat anti-rabbit IgG and the IRDye 680
CW goat anti-mouse IgG antibodies (LICOR Bioscience),
the NC membrane was scanned, analyzed, and quantified
with Odyssey Infrared Imaging system equipped with the
Odyssey v3.0 software (LICOR Bioscience). Additional de-
tails are available in supplemental methods.
Results
Clinical features
Six unrelated families with 12 affected males with the charac-
teristic combination of spondylometaphyseal dysplasia and
CNS hypomyelination were identified (Supplemental
Tables 1 and 2). Clinical features were remarkably homoge-
nous. Gestational and perinatal history were uneventful. The
children initially had a period of normal development, ranging
from 8 to 36months. In some cases, dysmorphic features were
noted during this period, including depressed nasal bridge and
midface hypoplasia. Patients never either gained the ability to
walk independently or gained independent ambulation with
significant delays (14–60 months), sometimes only to lose
independent ambulation again within a few years (with the
exception of patients 11 and 12 who had normal early mile-
stones). Subsequently, gradual loss of motor function ensued,
sometimes after a described plateau or slowing of develop-
mental milestones. Onset of gait abnormalities was between
12 and 24 months (with two exceptions, in whom disease
onset was reported at 4.5 and 6 years). Gait abnormalities were
due to spasticity, ataxia, proximal weakness, and joint contrac-
tures. Cognitive function was mildly impaired in 5/7
individuals for whom data was available. Language was ad-
ditionally impaired by dysarthria in 6/12 individuals.
Extra-neurologic manifestations including skeletal, eye,
and lung abnormalities were present. Patients 10, 11, and 12
were noted to have a shortened nasal bridge. Joint contractures
were sometimes noted early in disease course (5/12 at presen-
tation), and enlarged joints were noted in almost all patients
(11/12) over time. Postnatal growth failure, with borderline or
frank short stature, was noted in all patients where height
measurements were available (n = 7) and stature was 2–7
SD below the norm, though head circumference was normal.
Scoliosis developed in all but one individual for whom this
data was available (10/11) and was present from an early age
in most. Nystagmus was noted in 10/12 individuals. Vision
loss was seen in 8/12 individuals, associated with features of
macular degeneration, achromatopsia, optic nerve atrophy and
in one individual a rod-cone dystrophy diagnosed on ERG
(patient 1). One child (patient 8) had moderate hearing loss.
Three individuals in one extended family (patients 5, 6, 7) had
pulmonary hypertension. Patient 12 had seizures. No addi-
tional extra-neurologic organ involvement was reported.
Seven of the 12 individuals were deceased at the time of
this review (ages 35 months to 37 years at time of death).
Causes of death included pulmonary hypertension (two chil-
dren) and aspiration pneumonia. The remaining five are alive
(ages 8–18 years old).
MRI imaging
All affected individuals in whom MR imaging was available
(9/12) showed hypomyelination, with T1 hyperintense or
isointense signal, and T2 hyperintensity diffusely involving
the cerebral white matter including the arcuate fibers, the in-
ternal capsule, and the corpus callosum (Fig. 1), though in
some individuals, these were spared. The basal ganglia,
brainstem, and cerebellum were relatively spared, though sig-
nal abnormalities were seen in the middle and superior cere-
bellar peduncles and in some individuals also the hilus of the
dentate. There was mild loss of white matter volume and thin-
ning of the corpus callosum, without evident volume loss of
basal ganglia and cerebellum. No abnormalities were evident
on susceptibility-weighted images or diffusion-weighted im-
ages, where available. No contrast enhancement was seen
where available.
Skeletal imaging
Patients 1–4 and 7 and 8 had sufficient images for review
(Supplemental Table 3). Skeletal abnormalities were present
in images collected as early as 16 months but were also pro-
gressive and degenerative in nature on images of individuals
in the teenage years (Fig. 2). In the hands, brachydactyly and
clinodactyly with flat, shortened metacarpals and phalanges
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were universally seen, with variable amounts of coned epiph-
yses. In long bones, all individuals had changes in metaphyses
and physis, ranging from mild flaring seen early in disease to
severe irregular sclerosis at the metaphyses of the long bones,
progressive in older patients. In severe cases, epiphyseal irreg-
ular sclerosis developed over time at the knees, elbows, and
wrists. Vertebral abnormalities were common and included
end plate irregularity in milder cases and in more severe cases
anterior central beaking with vertebra plana, posterior
scalloping of lumbar vertebrae, and evolution of severe
kyphoscoliosis. In a few cases, there was narrow
interpeduncular distance. The pelvis was notable for flat ace-
tabula, coxa valga or coxa vara, squared iliac wings, thick
pubic rami, and progressive sclerosis of femoral epiphyses
with coxa magna in some individuals. Diffuse osteopenia
was a common finding and present early in most cases.
Genetic findings
In all six families, maternally inherited or de novo mutations
in or near exon 7 of AIFM1 were identified based on whole-
exome sequencing (Table 1 and Fig. 3). Patient 4 (family 3)
has a de novo c.710A > G (p.(Asp237Gly)) mutation identical
to the mutation previously reported in two H-SMD families by
Mierzewska et al. [7]. Patients 2 and 3 (family 2) had a
c.710A > T (p.(Asp237Val)) mutation at the same nucleotide
position. Patients 5, 6, and 7, from family 4, carried the mis-
sense variant c.705G > C (p.(Gln235His)). Patient 1 (family 1)
Fig. 1 MRI findings in H-SMD. Axial T2-weighted images (a–c, e–g, i–
k) and sagittal T1-weighted images (d, h, l) of patient 7 at age 4 years
(first row), patient 8 at age 5 years (second row), and patient 1 at age
4 years (third row). The supratentorial white matter shows a diffusely
elevated T2 signal (b, c, f, g, j, k), with unremarkable T1 signal (d, h,
l) indicating hypomyelination. Signal of the basal ganglia is normal (b, f,
j). The cerebellum has a normal volume (a, d, e, h, i, l). Signal of the
superior cerebellar peduncles is hyperintense in all patients (a, e, i).
Patient 7 has also signal elevation of the hilus of the dentate nucleus
(a). Patient 8 of the external part of the middle cerebellar peduncle (e).
Patient 1 has relatively better myelination of the brainstem, corpus
callosum and deep gray nuclei
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Fig. 2 Spondylometaphyseal dyplasia in H-SMD. a Common findings
in patients included changes in the metaphyses and epiphyses of long
bones, including mild flaring, pelvic abnormalities including flat
acetabula, squared iliac wings, and thick pubic rami, as well as
vertebral abnormalities including end plate irregularity and kyphosis. b
In some patients over time, vertebral anomalies evolved to include
anterior central beaking with vertebra plana, posterior scalloping of
lumbar vertebrae, and evolution of severe kyphoscoliosis. c In the
hands, brachydactyly and clinodactyly with flat, shortened metacarpals
and phalanges were universally seen, with variable amounts of coned
epiphyses. In older individuals, irregular sclerosis was seen over time. d
In metaphyses and epiphyses of long bones, severe irregular sclerosis was
seen over time, present here at the knees
Table 1 Genetic variants in AIFM1 identified by patient
Family Base pair Amino acid Evidence of pathogenicity [1] Variant clasification [1]










Family 3 (P4) [5] c.710A > G p.(Asp237Gly) (identical mutation
as previously published [7]







Family 4 (P5, 6, 7) c.705G > C p.(Gln235His) PS3
PM2
PP1 (very strong family segregation)
PP3
Likely pathogenic






Family 6 (P9, 10, 11, 12) [4] c.697-44 T > G NA PS3
PM2
PP1 (very strong family segregation)
PP3 (intronic (44 nt 5′ of splice site,
disrupts predicted branch point) [13])
Likely pathogenic
Genetic variants in AIFM1 identified by patient with their classification based on Richards et al. 2015 [14]
PM pathogenic moderate, PP pathogenic supporting, PS pathogenic strong, NA not available.
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and patient 8 (family 5) both had the synonymous mutation
c.720C > T (p.(Asp240Asp)); this variant was de novo in
patient 1 and maternally inherited in patient 8. Patients 9, 10,
11, and 12, all from family 6, had a rare variant 44 bp from the
3′ splice site of exon 7 at position c.697-44 T > G that is
predicted to disrupt the intron branch point (Supplemental
Table 4) [13]. The carrier status of the mothers of families 1,
2, 3, and 5 were confirmed by Sanger sequencing. The muta-
tions in families 1 and 3 were found to be de novo while
family 2 and 5 were maternally inherited. No variant was
present in ExAC or dbSNP 147. However, the ExAC database
does report a single female individual heterozygous for
c.705G > C (p.(Gln235His)), the same nucleotide position
and resulting amino acid change seen in family 4.
The presence in all reported cases of H-SMD of maternally
inherited or de novo mutations confined to an approximately
70 bp region of AIFM1 in and near exon 7, together with a
phenotype distinct from previously reported AIFM1 muta-
tions, leads us to suspect these mutations result in loss of
functional and stable AIFM1. We used the Human Splicing
Finder (v3.0) tool to predict the impact each of the mutations
may have on the splicing of AIFM1 [13]. Each of the exonic
mutations was predicted to disrupt BExonic Splicing
Enhancer^ motifs and potentially result in an alteration of
splicing (Supplemental Table 4).
AIFM1 expression
To investigate the impact of the patient mutations on AIFM1
expression, we compared AIFM1 messenger RNA (mRNA)
and protein levels in patient fibroblasts and transdifferentiated
osteoblasts to equivalent cells from unrelated controls.
Osteoblasts were selected in order to obtain cells modeling
affected tissue, and transdifferentiation was confirmed by ex-
pression of osteogenic markers (RUNX and ALP,
Supplemental Fig. 1) and staining (Fig. 4a). Analysis by quan-
titative real-time PCR found that AIFM1 mRNAwas signifi-
cantly decreased in patient osteoblasts (n = 3) (p = 0.002)
when compared to controls (n = 3) (Fig. 4c) and also in patient
1 (analyzed, separately; supplementary Fig. 2A). Analysis of
osteoblasts by western blot found that AIFM1 protein levels
were significantly reduced in patients (n = 3) when compared
to controls (n = 3) (p = 0.01) (Fig. 4d); this was confirmed by
testing cell lines of a fourth patient in a separate experiment
(patient 1, supplementary Fig. 2B). Importantly, the patient
cell lines tested included the p.(Gln235His) missense
50nt
10kb
Family 1; c.720C>T; p.(Asp240Asp)
Family 2; c.710A>T; p.(Asp237Val)
Family 3; c.710A>G; p.(Asp237Gly) 
Family 4; c.705G>C; p.(Gln235His)




Family 1 Family 2 Family 3
Family 4 Family 6
Family 5












mutations in AIFM1. a Pedigrees
of each H-SMD families with
subjects of this study indicated.
Where the mother is not noted to
be a carrier, the mother has been
sequenced and the variant is de
novo. b AIFM1 refseq transcripts
showing known alternative
splicing events. c H-SMD-
associated mutations in AIFM1
are all near exon 7 splice acceptor
site. The predicted intron branch
point motif is indicated in red text.
The Human Splicing Finder tool
predicts the c.697-44 T > G
mutation will disrupt the function
of this branch point. dMotifs of
primary sequence conservation
surrounding each H-SMD-
associated mutation in AIFM1
based on alignment of 15
mammalian species using
WebLogo. The size of the letters
indicates degree of conservation
and where more than one
nucleotide is visible suggests
variation across species
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mutation, the p.(Asp240Asp) synonymous mutation, and the
c.697-44 T > G intronic branch point mutation indicating that
each of these three classes of mutation result in a similar loss
of AIFM1 expression in osteoblasts. In fibroblasts, AIFM1
protein expression was very low in controls and undetectable
in patients, despite considerable mRNA expression
(supplementary Fig. 3).
Discussion
Here, we show that a rare X-linked condition characterized by
hypomyelinating leukodystrophy and spondylometaphyseal
dysplasia (H-SMD) is caused by specific AIFM1 mutations,
all located in a small part of the gene comprising about
70 bp around the start of exon 7. The combination of
hypomyelination and skeletal dysplasia allows clinical diag-
nosis and should enable identification of additional patients,
although this disorder seems to be extremely rare, because of
its rarity both in large cohorts of white matter disease (NIW
and AV) and in of skeletal dysplasias (ASF). Neurological
course is relatively mild, comparable with 4H syndrome
and much milder than in PMD, with a stable phase of variable
length followed by slow neurological decline, manifesting in
progressive spasticity and ataxia. The prominent skeletal ab-
normalities also contribute to motor impairment.
Mitochondrial apoptosis-inducing factor 1 (encoded by
AIFM1, located on Xq26.1) is a protein with multiple canon-
ical roles. AIFM1 has redox activity that aids in oxidative
phosphorylation, is proposed to function in the mitochondria
to assemble and/or maintain the mitochondrial respiratory
complexes I and III, and plays a role in apoptosis, triggering
caspase-independent programmed cell death under apoptotic
stimuli [15–17].
Why this specific phenotype with its characteristic com-
bination of myelin deficit and bone abnormalities is caused
by this subset of AIFM1 mutations is not known. In a
recent study on the effect of several AIFM1 mutations on
protein structure and function, one mutation situated
in close vicinity to the mutations described here,
p.(Val243Leu), had virtually no effect on the folding,
redox, and DNA-binding properties of the protein [18].
Even more intriguing, different variants in AIFM1 have
previously been shown to be associated with diverse neu-
rological disorders featuring intellectual disability, sensory
hearing loss, neuropathy, and T2 hyperintensity in the
Fig. 4 AIFM1 in fibroblasts and transdifferentiated osteoblasts. a
Alizarin red, alkaline phosphatase (ALP) activity, and von Kossa
staining of fibroblasts and transdifferentiated osteoblasts, confirming
successful transdifferentiation. These stains provide a qualitative
indication of the capability of the cells to mineralize; plates were not
normalized for cell number. b Western blot of AIFM1 and actin in
transdifferentiated osteoblasts (day 21). kDa kiloDalton. c AIFM1
relative mRNA expression in transdifferentiated osteoblasts (day 21), in
relation to the housekeeping gene YWHAZ. d Depicts AIFM1 protein
expression normalized to Actin in osteoblasts. Error bars indicate
standard error of the mean (SEM, n = 3)
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striatum on magnetic resonance imaging (MRI), with some
patients presenting with a mitochondrial phenotype and
abnormalities in respiratory chain function [19]. Specific
phenotypes include auditory neuropathy spectrum disorder
[20], a severe X-linked mitochondrial encephalopathy [21,
22], and Cowchock syndrome, an axonal sensorimotor
neuropathy with deafness and mental retardation [23, 24].
This suggests that there is a tight genotype-phenotype re-
lationship, causing these different clinical manifestations.
The specific clinical presentation of H-SMD is clearly dis-
tinct from other conditions previously associated with muta-
tions in AIFM1. Given all known cases of H-SMD have a
single base mutation within a 70-nt region flanking the exon
7 acceptor splice site, we suspect that mutations in this specific
region of AIFM1 result in a common functional consequence
that specifically gives rise to H-SMD. Three of the five known
H-SMD-associated AIFM1 mutations are missense, and it is
possible that the encoded amino acid changes may result in
disrupted AIFM1 protein function. However, as three H-SMD
families have mutations in this region that do not directly alter
the encoded protein sequence, it is most likely that the primary
functional consequence of all five known H-SMD mutations
(including missense, synonymous, and intronic) is a specific
defect in mRNA splicing. This hypothesis is consistent with
our findings that AIFM1 mRNA levels are significantly re-
duced in patient-derived osteoblast cells and AIFM1 protein
levels reduced to near the limits of detection. We did attempt
to detect evidence of a specific alteration in AIFM1 splicing by
quantitative real-time PCR using a series of exon/exon specif-
ic primer pairs across the gene. However, we could not detect
any definitive changes between patient and control cell lines.
Thus, although the association of these mutations within a
small genomic area is compelling, the precise mechanism by
which they disrupt AIFM1 function is still unclear.
H-SMD is not the only disorder with spondylometaphyseal
involvement and associated neurological symptoms. One ex-
ample is TRPV4-related disorders. Mutations in TRPV4,
encoding a calcium-permeable cation channel, give rise to
either skeletal dysplasia, sometimes with early lethality, or
peripheral neuropathy or a combination of both [25–27].
Neither the pathogenic mechanisms leading to these diverse
phenotypes affecting completely different tissues nor the ef-
fects of specific mutations are yet understood. The example of
H-SMD demonstrates how significant genotype-phenotype
correlations may be in certain genes and emphasizes the im-
portance of tissue-specific impacts of gene mutations.
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